Profile data is unavailable for this security.
About the company
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
- Revenue in INR (TTM)25.29bn
- Net income in INR1.71bn
- Incorporated1984
- Employees1.50k
- LocationAarti Drugs LtdMahendra Industrial Estate,Ground Floor, Road No 29, Plot No 109-D,MUMBAI 400022IndiaIND
- Phone+91 2 224019025
- Fax+91 2 224073462
- Websitehttps://www.aartidrugs.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innova Captab Ltd | -100.00bn | -100.00bn | 25.89bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.72 | -- | 6.26 | -- | -- | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 26.13bn | 1.23k | -- | 82.63 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| SeQuent Scientific Ltd | 13.75bn | -1.29bn | 28.95bn | 478.00 | -- | -- | -- | 2.11 | -5.18 | -5.18 | 55.33 | -- | -- | -- | -- | 28,769,920.00 | -- | 2.33 | -- | 3.67 | 42.78 | 42.47 | -8.97 | 2.59 | -- | -0.3894 | -- | 17.27 | 0.5728 | 10.84 | -395.83 | -- | 12.88 | -- |
| Supriya Lifescience Ltd | 5.54bn | 1.20bn | 29.67bn | 392.00 | 24.62 | -- | 21.93 | 5.35 | 14.97 | 14.97 | 68.93 | -- | -- | -- | -- | 14,144,410.00 | -- | 20.77 | -- | 29.06 | 61.94 | 55.83 | 21.72 | 24.33 | -- | 63.63 | -- | 2.02 | -13.04 | 16.70 | -40.81 | 59.41 | 85.55 | -- |
| Indoco Remedies Ltd | 17.96bn | 1.02bn | 30.30bn | 6.10k | 30.07 | -- | 16.46 | 1.69 | 10.93 | 10.93 | 192.26 | -- | -- | -- | -- | 2,943,454.00 | -- | 6.07 | -- | 8.90 | 69.39 | 65.35 | 5.61 | 6.30 | -- | 5.11 | -- | 14.79 | 8.30 | 9.81 | -8.11 | 28.15 | 8.25 | 17.61 |
| Dishman Carbogen Amcis Ltd | 25.80bn | -1.54bn | 30.96bn | 1.30k | -- | -- | 21.01 | 1.20 | -9.84 | -9.84 | 164.35 | -- | -- | -- | -- | 19,919,850.00 | -- | 0.4699 | -- | 0.5665 | 76.93 | 74.36 | -5.98 | 1.82 | -- | -0.1245 | -- | 202.76 | 12.72 | 7.32 | -265.46 | -- | 21.54 | -- |
| Gufic BioSciences Ltd | 7.85bn | 841.95m | 31.98bn | 1.63k | 36.99 | -- | 30.32 | 4.08 | 8.62 | 8.62 | 80.38 | -- | -- | -- | -- | 4,820,074.00 | -- | 12.30 | -- | 23.08 | 51.08 | 44.91 | 10.73 | 9.84 | -- | 8.22 | -- | 1.39 | -11.36 | 17.47 | -16.84 | 37.06 | 86.82 | 14.87 |
| Hikal Ltd | 18.16bn | 716.22m | 35.34bn | 2.14k | 49.38 | -- | 19.23 | 1.95 | 5.80 | 5.80 | 147.17 | -- | -- | -- | -- | 8,477,077.00 | -- | 5.86 | -- | 8.87 | 52.08 | 45.41 | 3.94 | 6.37 | -- | 2.78 | -- | 10.14 | 4.13 | 9.25 | -51.16 | 0.2973 | 23.35 | 4.42 |
| Unichem Laboratories Ltd | 16.75bn | 145.69m | 39.08bn | 3.12k | 268.66 | -- | 29.99 | 2.33 | 2.07 | 2.07 | 234.69 | -- | -- | -- | -- | 5,364,373.00 | -- | -1.38 | -- | -1.66 | 59.94 | 56.15 | 0.8696 | -3.60 | -- | -0.9613 | -- | -- | 5.76 | 10.51 | -711.67 | -- | -22.60 | -- |
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 42.04bn | 1.50k | 24.57 | 3.28 | 18.85 | 1.66 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 42.79bn | 338.00 | 31.16 | -- | 24.65 | 7.08 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 44.64bn | 1.40k | 22.94 | -- | 16.87 | 2.44 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.23bn | -6.71m | 48.88bn | 1.03k | -- | -- | 45.97 | 4.35 | -0.0714 | -0.0714 | 131.44 | -- | -- | -- | -- | 10,873,050.00 | -- | 3.89 | -- | 4.92 | 64.42 | 60.22 | -0.0538 | 9.29 | -- | 1.16 | -- | 10.65 | -8.33 | 5.82 | -153.54 | -- | 14.58 | -- |
| Orchid Pharma Ltd | 8.12bn | 1.25bn | 51.72bn | 838.00 | 35.78 | -- | 32.54 | 6.37 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
Data as of May 10 2024. Currency figures normalised to Aarti Drugs Ltd's reporting currency: Indian Rupee INR
6.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 31 Mar 2024 | 4.62m | 5.02% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 533.97k | 0.58% |
| Mellon Investments Corp.as of 04 Apr 2024 | 224.48k | 0.24% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 98.28k | 0.11% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 93.16k | 0.10% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 55.52k | 0.06% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 49.98k | 0.05% |
| TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 33.65k | 0.04% |
| State Street Global Advisors Ltd.as of 04 Apr 2024 | 25.42k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 24.82k | 0.03% |
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
